

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/012568 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number:  
PCT/GB2004/003342

(22) International Filing Date: 30 July 2004 (30.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0317826.6 30 July 2003 (30.07.2003) GB

(71) Applicant (for all designated States except US): **THE QUEEN'S UNIVERSITY OF BELFAST** [GB/GB]; University Road, Belfast BT7 1NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHNSTON, Patrick, Gerard** [GB/GB]; Department of Oncology, University Floor, Belfast City Hospital, 97 Lisburn Road, Belfast BT9 7AB (GB). **LONGLEY, David, Broderick** [GB/GB]; 24 Woodland Avenue, Lambeg, Lisburn, BT27 4PJ (GB). **MAXWELL, Pamela, Joan** [GB/GB]; 16 Lapwing Park, Teal Rocks, Newtownards BT23 8FL (GB).

(74) Agent: **MURGITROYD & COMPANY**; Scotland House, 165-169 Scotland Street, Glasgow G5 8PL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY METHOD

(57) Abstract: Methods of determining susceptibility to resistance to anti-cancer drugs such as fluoropyrimidines, antimetabolites and platinum-containing compounds are described. DNA microarray technology was used to investigate changes in the transcriptional profile of the MCF-7 breast cancer cell line following treatment with fluoropyrimidines. Upregulated genes included the genes encoding Raf, K-ras, SLAP, phosphoinositide 3-kinase, COP9 homolog (HCOP9), apoptosis specific protein, APO-1 cell surface antigen, FLIP protein, cyclin G, CDC2, cyclin-dependent protein kinase -2, thymosin  $\beta$ -10, myosin light chain (MLC-2), gelsolin, thymosin  $\beta$ -4, SSAT, spermidine synthase, spermidine aminopropyltransferase, MAT-8 protein, annexin II, annexin IV, FGF receptor 2, transmembrane 4 superfamily protein, chaperonin 10, enoyl-CoA hydratase, nicotinamide nucleotide transhydrogenase, ribosomal protein S28, ribosomal protein L37, L23 mRNA for putative ribosomal protein, and ribosomal protein L7. Also described are assays for identifying novel chemotherapeutic agents.



WO 2005/012568 A2